An Early Phase 1 interventional study of Irinotecan and temozolomide in Neuroblastoma (NB), sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Memorial Sloan Kettering Cancer Center · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.
Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 11th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 1, reaches primary completion later than 4 of the 11 other live ones, and was the 5th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:
Giselle Sholler · Sites in United States
Ages 1–30
Shaare Zedek Medical Center · Sites in Israel
Ages 12 mo–21 yrs
Steven DuBois, MD · Sites in United States
Ages 1–30
Giselle Sholler · Sites in United States
Ages 1–21
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18 mo–19 yrs
By country, each count listing its studies:
naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is above the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 62 across the 17 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 8 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center: 5 open now, 10 under way, none of them phase 3. Of 40 finished, 13 (33%) have results posted.
Among the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, this one is the 16th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2017, is one of 16 in phase 1, and was the 44th registered.
Memorial Sloan Kettering Cancer Center’s Neuroblastoma studies by the year they started, since 1987.
5 of the studies testing naxitamab in Neuroblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01757626Memorial Sloan Kettering Cancer CenterCombination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | 2026-12 |
| NCT06013618Sun Yat-sen UniversityClinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | 2026-12-31 |
| NCT03189706Memorial Sloan Kettering Cancer CenterStudy of Chemoimmunotherapy for High-Risk Neuroblastoma | 2027-06 |
| NCT06047535SciClone PharmaceuticalsNaxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | 2027-06-15 |
| NCT07027748Steven DuBois, MDFeasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 17 studies testing naxitamab in Neuroblastoma, from their registry updates:
Among Memorial Sloan Kettering Cancer Center’s 51 in Neuroblastoma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
High-risk NB as defined as any of the following:
Patients fulfill one of the following criteria:
If they only have osteomedullary disease at protocol enrollment, they should have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each cycle consists of four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF.
Drug: Irinotecan · Drug: temozolomide · Biological: Hu3F8 · Drug: GM-CSF
50mg/m\^2/day IV will be administered from day 1-5
(given concurrently with Irinotecan) 150mg/m\^2/day orally
2.25mg/kg IV will be administered on days 2, 4, 8 and 10
250mcg/m2/day SC will be administered on days 6-10
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
The regimen will be considered safe if there are no toxicities requiring discontinuation of therapy in at least 9/10 patients during the first two cycles.
Time frame: 2 years
response rate (CR+PR)
Response assessment will be based on the best response over the course of four cycles. Disease response for NB will use the International NB Response Criteria. Patients who withdraw from the study prior to cycle 4 with \< partial response will also not be considered evaluable for response and will be replaced.
Time frame: 2 years
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Supporting information: Statistical analysis plan
Started Jun 2017 (actual). Primary completion is estimated for Jun 2027, 120 months after the start.
Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's planned 120 months is above that.
Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naxitamab
Memorial Sloan Kettering Cancer Center →